I posted a while back my review of the whole group versus the historical control group used in recent BP Alz failure based upon the KEM charts.
Our whole group average score seems about the same as historical controls. So it would appear we have the strong responders holding up the average of a few that are likely doing worse than historical controls.
It isn’t so clear cut, but IF the analysis and next trial correctly identifies the cause of some doing much better than SOC and others not so much, we have a winner.
Hence imo Missling is spending more time in an effort to avoid failure.
That’s the right approach, but no guarantee of success.
Market Data 
Markets 
AI
